Latuda lurasidone regulatory update

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary submitted 2 sNDAs to FDA for Latuda lurasidone to treat adult patients with depressive episodes associated with bipolar I disorder as a monotherapy...